$0.9996
At close: Apr 29, 7:22 PM EDT
$1.00
0.000400.04%
After Hours: 7:22 PM EDT
Comments
Loading...
Coherus BioSciences Analyst Ratings and Price Targets | NASDAQ:CHRS | Benzinga
Coherus BioSciences Inc has a consensus price target of $9.01 based on the ratings of 9 analysts. The high is $21 issued by Mizuho on November 16, 2022. The low is $1.05 issued by UBS on April 24, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., UBS, and HC Wainwright & Co. on April 29, 2025, April 24, 2025, and March 11, 2025, respectively. With an average price target of $5.02 between HC Wainwright & Co., UBS, and HC Wainwright & Co., there's an implied 401.67% upside for Coherus BioSciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
UBS
Baird
Truist Securities
Barclays
1calculated from analyst ratings
Analyst Ratings for Coherus BioSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/29/2025 | Buy Now | 600% | HC Wainwright & Co. | Douglas Tsao52% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2025 | Buy Now | 5% | UBS | Ashwani Verma44% | $1.5 → $1.05 | Maintains | Neutral | Get Alert |
| 03/11/2025 | Buy Now | 600% | HC Wainwright & Co. | Douglas Tsao52% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2025 | Buy Now | 600% | HC Wainwright & Co. | Douglas Tsao52% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 500% | Baird | Colleen Kusy34% | $4 → $6 | Maintains | Outperform | Get Alert |
| 12/04/2024 | Buy Now | 600% | HC Wainwright & Co. | Douglas Tsao52% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 300% | Baird | Colleen Kusy34% | $8 → $4 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 1100% | HC Wainwright & Co. | Douglas Tsao52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 1100% | HC Wainwright & Co. | Douglas Tsao52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 50% | UBS | Ashwani Verma44% | $4 → $1.5 | Downgrade | Buy → Neutral | Get Alert |
| 08/05/2024 | Buy Now | 1100% | HC Wainwright & Co. | Douglas Tsao52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 700% | Baird | Colleen Kusy34% | $9 → $8 | Maintains | Outperform | Get Alert |
| 05/24/2024 | Buy Now | 1100% | HC Wainwright & Co. | Douglas Tsao52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 600% | Truist Securities | Robyn Karnauskas55% | $8 → $7 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 1100% | HC Wainwright & Co. | Douglas Tsao52% | $11 → $12 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 1000% | HC Wainwright & Co. | Douglas Tsao52% | $13 → $11 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 1200% | HC Wainwright & Co. | Douglas Tsao52% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2024 | Buy Now | 800% | Baird | Colleen Kusy34% | $11 → $9 | Maintains | Outperform | Get Alert |
| 01/23/2024 | Buy Now | 700% | Truist Securities | Robyn Karnauskas55% | $12 → $8 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 1200% | HC Wainwright & Co. | Douglas Tsao52% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 12/07/2023 | Buy Now | 1200% | HC Wainwright & Co. | Douglas Tsao52% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 11/28/2023 | Buy Now | 1100% | Truist Securities | Robyn Karnauskas55% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/17/2023 | Buy Now | 1000% | Baird | Colleen Kusy34% | → $11 | Initiates | → Outperform | Get Alert |
| 11/08/2023 | Buy Now | — | Maxim Group | Jason McCarthy42% | — | Downgrade | Buy → Hold | Get Alert |
| 11/07/2023 | Buy Now | 1200% | HC Wainwright & Co. | Douglas Tsao52% | $20 → $13 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 600% | Barclays | Balaji Prasad52% | $8 → $7 | Maintains | Overweight | Get Alert |
| 09/26/2023 | Buy Now | 1900% | Truist Securities | Robyn Karnauskas55% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2023 | Buy Now | 1900% | HC Wainwright & Co. | Douglas Tsao52% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 600% | UBS | Ashwani Verma44% | $11 → $7 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 1900% | HC Wainwright & Co. | Douglas Tsao52% | $24 → $20 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 1100% | Citigroup | Robyn Karnauskas55% | → $12 | Initiates | → Buy | Get Alert |
| 07/14/2023 | Buy Now | 1900% | Truist Securities | Robyn Karnauskas55% | $22 → $20 | Maintains | Buy | Get Alert |
| 06/28/2023 | Buy Now | 2100% | Truist Securities | Robyn Karnauskas55% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 2100% | Truist Securities | Robyn Karnauskas55% | $24 → $22 | Maintains | Buy | Get Alert |
| 06/20/2023 | Buy Now | 2300% | HC Wainwright & Co. | Douglas Tsao52% | → $24 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 2300% | Truist Securities | Robyn Karnauskas55% | → $24 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 2300% | HC Wainwright & Co. | Douglas Tsao52% | → $24 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | 2300% | HC Wainwright & Co. | Douglas Tsao52% | → $24 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 700% | Barclays | Balaji Prasad52% | $13 → $8 | Maintains | Overweight | Get Alert |
| 05/09/2023 | Buy Now | 2300% | HC Wainwright & Co. | Douglas Tsao52% | $26 → $24 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | 2300% | Truist Securities | Robyn Karnauskas55% | → $24 | Initiates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 1000% | UBS | Ashwani Verma44% | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 03/08/2023 | Buy Now | 1200% | Barclays | Balaji Prasad52% | $15 → $13 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 2500% | HC Wainwright & Co. | Douglas Tsao52% | $30 → $26 | Maintains | Buy | Get Alert |
| 11/16/2022 | Buy Now | 2000% | Mizuho | Salim Syed43% | $28 → $21 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 1000% | JP Morgan | Chris Schott60% | $13 → $11 | Maintains | Neutral | Get Alert |
| 08/16/2022 | Buy Now | 2700% | Mizuho | Salim Syed43% | $25 → $28 | Maintains | Buy | Get Alert |
| 06/14/2022 | Buy Now | 600% | UBS | Ashwani Verma44% | → $7 | Initiates | → Neutral | Get Alert |
| 05/20/2022 | Buy Now | 2400% | Mizuho | Salim Syed43% | $30 → $25 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 1400% | Barclays | Balaji Prasad52% | $20 → $15 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Coherus BioSciences (CHRS) stock?
The latest price target for Coherus BioSciences (NASDAQ:CHRS) was reported by HC Wainwright & Co. on April 29, 2025. The analyst firm set a price target for $7.00 expecting CHRS to rise to within 12 months (a possible 600.00% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Coherus BioSciences (CHRS)?
The latest analyst rating for Coherus BioSciences (NASDAQ:CHRS) was provided by HC Wainwright & Co., and Coherus BioSciences reiterated their buy rating.
When was the last upgrade for Coherus BioSciences (CHRS)?
The last upgrade for Coherus BioSciences Inc happened on March 28, 2023 when UBS raised their price target to $11. UBS previously had a neutral for Coherus BioSciences Inc.
When was the last downgrade for Coherus BioSciences (CHRS)?
The last downgrade for Coherus BioSciences Inc happened on August 16, 2024 when UBS changed their price target from $4 to $1.5 for Coherus BioSciences Inc.
When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on April 29, 2025 so you should expect the next rating to be made available sometime around April 29, 2026.
Is the Analyst Rating Coherus BioSciences (CHRS) correct?
While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a reiterated with a price target of $7.00 to $7.00. The current price Coherus BioSciences (CHRS) is trading at is $1.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
